IO Biotech Q3 2024 GAAP EPS $(0.36) Misses $(0.27) Estimate, Ended Third Quarter With Approximately $80M In Cash And Cash Equivalents; The Company Continues To Expect Its Cash Position Will Support Operations Into Q4 Of 2025

Benzinga11-12

IO Biotech (NASDAQ:IOBT) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.27) by 33.33 percent. This is a 16.28 percent increase over losses of $(0.43) per share from the same period last year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2482706707?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-12 20:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2482706707","market":"us","top_or_hot":-1,"title":"IO Biotech Q3 2024 GAAP EPS $(0.36) Misses $(0.27) Estimate, Ended Third Quarter With Approximately $80M In Cash And Cash Equivalents; The Company Continues To Expect Its Cash Position Will Support Operations Into Q4 Of 2025","media":"Benzinga","content":"<html><body><p>IO Biotech (NASDAQ:IOBT) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.27) by 33.33 percent. This is a 16.28 percent increase over losses of $(0.43) per share from the same period last year.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IO Biotech Q3 2024 GAAP EPS $(0.36) Misses $(0.27) Estimate, Ended Third Quarter With Approximately $80M In Cash And Cash Equivalents; The Company Continues To Expect Its Cash Position Will Support Operations Into Q4 Of 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIO Biotech Q3 2024 GAAP EPS $(0.36) Misses $(0.27) Estimate, Ended Third Quarter With Approximately $80M In Cash And Cash Equivalents; The Company Continues To Expect Its Cash Position Will Support Operations Into Q4 Of 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-12 20:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/earnings/24/11/41898237/io-biotech-q3-2024-gaap-eps-0-36-misses-0-27-estimate-ended-third-quarter-with-approximately-80m-in><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>IO Biotech (NASDAQ:IOBT) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.27) by 33.33 percent. This is a 16.28 percent increase over losses of $(0.43)...</p>\n\n<a href=\"https://www.benzinga.com/news/earnings/24/11/41898237/io-biotech-q3-2024-gaap-eps-0-36-misses-0-27-estimate-ended-third-quarter-with-approximately-80m-in\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IOBT","symbol_name":"IO Biotech, Inc.","start_time":0,"source_url":"https://www.benzinga.com/news/earnings/24/11/41898237/io-biotech-q3-2024-gaap-eps-0-36-misses-0-27-estimate-ended-third-quarter-with-approximately-80m-in","article_id":"2482706707","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2482706707","pubTimestamp":1731415895,"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"IO Biotech (NASDAQ:IOBT) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.27) by 33.33 percent. This is a 16.28 percent increase over losses of $(0.43) per share from the","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"IOBT":"IO Biotech, Inc.","IO":"离子地球物理"},"translate_title":"IO Biotech 2024年第三季度GAAP每股收益(0.36)美元低于预期(0.27)美元，截至第三季度末现金和现金等价物约为8000万美元；该公司继续预计其现金状况将支持2025年第四季度的运营","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IO":1,"IOBT":1},"content_text":"IO Biotech (NASDAQ:IOBT) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.27) by 33.33 percent. This is a 16.28 percent increase over losses of $(0.43) per share from the same period last year.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2482706707"}